DAV announces historic resource at South Harz Potash Project

Published 15-NOV-2017 12:24 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Davenport Resources (ASX:DAV) this morning announced a historic resource on its 100%-owned Ebeleben mining licence in the South Harz region of Germany.

Ebeleben is one of three perpetual mining licences in the South Harz basin that DAV acquired from the German government agency Bodenverwertungs-und-verwaltungs GmbH (BVVG) recently. DAV now holds a total of more than 650 square kilometres in the South Harz.

Here you can see the location of the South Harz project:

Davenport resources licenses

The historic resource estimate for the Ebeleben licence is 356 million tonnes of 16.1% Potassium oxide (K2O) (57.4Mt contained K2O) in Sylvinite. That’s equivalent to 91 million tonnes of potassium chloride (KCI).

The company’s Managing Director Chris Bain explained that DAV anticipates that a minimum number of carefully located confirmation drill holes can readily validate these historic resources to allow conversion to JORC 2012 standard.

Yet it is still early days on the project and investors should seek professional financial advice if considering this stock for their portfolio.

The Ebeleben area is considered an extension of the Volkenroda Potash Mine that operated for more than 80 years to 1981.

The mining licence covers a band of Sylvanite potash mineralisation that extends from the now closed Volkenroda mine to DAV’s Grafentonna exploration licence. There are 12 potash holes that were drilled in two stages in the 1960s and 1980s within the licence area. There were also 18 hydrocarbon exploration drill holes sunk within the area.

This historic drilling provided a quite detailed picture of the lithostratigraphic structure and the predominantly Sylvanite minerology. Geological and hydrological conditions were considered to be largely similar to those in the adjacent Volkenroda mine and the potash salts were considered processable with the technology then in use at Volkenroda.

The potash bearing horizon is developed over the entire Ebeleben Mining Licence area with a varying thickness and K2O grades. Here is a map of the Ebeleben mining licence extending from the closed Volkenroda mine to Grafentonna exploration licence:

ebeleben borehole

The detailed information supporting the historic resource estimate announced today will allow DAV to fast track cost-effective brownfields evaluation of the area with the aim of reinvigorating the South Harz as a globally significant potash producing region.

To upgrade the Ebeleben historic resource to JORC 2012 standard DAV plans to do confirmatory drilling by twinning one or two of the 12 historic drill holes drilled specifically for Potash.

Further historic resources on the other mining licences acquired from BVVG will be released as the data is reviewed.

Once all data has been evaluated DAV intends to select priority areas with historic resources for drill testing. Areas will be prioritised based on the quality of the historic results and on available access and approval requirements for new drilling.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X